1. 1) Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int., 115 (Suppl. 5), 3–13 (2015).
2. 2) Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can. J. Urol., 21 (Suppl. 1), 57–63 (2014).
3. 3) Robert AA, Ranjodh SG. Clinical utility of denosumab for treatment of bone loss in men and women. Clin. Interv. Aging, 6, 119–124 (2011).10.2147/CIA.S14565
4. 4) Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol. Pharmacol., 55, 403–410 (1999).
5. 5) Webber MM, Bello-DeOcampo D, Quader S, Deocampo ND, Metcalfe WS, Sharp RM. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin. Exp. Metastasis, 17, 255–263 (1999).